

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above. 5.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

1 Myall



Section 1. Identifying Inform	nation						
Given Name (First Name) Nathaniel	2. Surname (Last Name) Myall	3. Date 07-July-2020					
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Heather Wakelee					
5. Manuscript Title Safety of Lorlatinib Following Alectinib- Cancer: A Case Series	-Induced Pneumonitis in T	wo Patients with ALK¬-Rearranged Non-Small Cell Lung					
6. Manuscript Identifying Number (if you kr	now it)						
Section 2. The Work Under Co	onsideration for Public	ration					
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No							
Section 3. Relevant financial	activities outside the s	submitted work.					
of compensation) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.					
Section 4. Intellectual Bronou	tre Dotonto () Commis	ula de					
intellectual Proper	ty Patents & Copyric	jnts					
Do you have any patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes V No					

Myall 2



Section 5. Polationships not severed phase
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Myall has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Myall 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Lei 1



Section 1. Identifying Inform	nation					
Given Name (First Name) Amy	2. Surname (Last Name) Lei	3. Date 07-July-2020				
4. Are you the corresponding author?	☐ Yes 🗸 No	Corresponding Author's Name Heather Wakelee				
5. Manuscript Title Safety of Lorlatinib Following Alectinib Cancer: A Case Series	-Induced Pneumonitis in T	wo Patients with ALK¬-Rearranged Non-Small Cell Lung				
6. Manuscript Identifying Number (if you k	now it)					
		_				
Section 2. The Work Under C	onsideration for Public	cation				
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No						
Section 3. Relevant financial	activities outside the s	submitted work.				
of compensation) with entities as descr	ribed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.				
Section 4. Intellectual Prope	rty Patents & Copyri <u>c</u>	ghts				
Do you have any patents, whether plan	nned, pending or issued, br	oadly relevant to the work? Yes V No				

Lei 2



Section 5. Polationships not severed shows
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Lei has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Lei 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1.	Identifying Inform	ation						
1. Given Name (Fi Heather	rst Name)	2. Surnar Wakelee	me (Last Nar	me)		3. Date 07-July-2020		
4. Are you the corresponding author? ✓ Yes No								
Cancer: A Case S	nib Following Alectinib-		neumoniti	s in Two Patients	with ALK	ল-Rearranged Non-Small Cell Lung		
Section 2.	The Work Under Co	onsidera [.]	tion for P	ublication				
any aspect of the s statistical analysis,	submitted work (including	but not lin	nited to grar			ent, commercial, private foundation, etc.) for udy design, manuscript preparation,		
Section 3. Relevant financial activities outside the submitted work.								
of compensation clicking the "Add Are there any rel	n) with entities as descri	bed in the port relation st?	instructionships that Yes	ns. Use one line fo	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.		
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Gilead		✓				Clinical Research Grant		
AztraZeneca			✓	✓		Advisor or consultant, honoraria		
Covery			✓		√	Advisor or consultant, research funding to institution		
anssen			✓			Advisor or consultant		
Daiichi Sankyo, INC			✓			Advisor or consultant		
Helsinn			✓			Advisor or consultant		
∕lirati			✓			Advisor or consultant		



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Takeda			✓		Advisor or consultant (not compensated)
CellWorks			✓		Advisor or consultant (not compensated)
Genentech/Roche			✓	✓	Advisor or consultant (not compensated), research funding to institution
Merck			✓	✓	Advisor or consultant (not compensated), research funding to institution
Clinical Care Options Oncology, LLC			✓		CME Presentation (travel funding)
Fishawack Facilitate LTD			\checkmark		CME Presentation (travel funding)
Medscape			✓		CME Presentation (travel funding)
Onclive/Intellisphere LLC			✓		CME Presentation (travel funding)
Phillips Gilmore Oncology (2018)			✓		CME Presentation (travel funding)
Physicians Education Resource LLC/MJH Targeted Oncology)			✓		CME Presentation (travel funding)
Potomac Center for Medical Education (Rockpointe)			✓		CME Presentation (travel funding)
Prime Oncology LLC (2018)			✓		CME Presentation (travel funding)
Primo (2018)			✓		CME Presentation (travel funding)
Research to Practice			✓		CME Presentation (travel funding)
JpToDate		✓			
WebMD Health			√		CME Presentation (travel funding)
Novartis			✓		Honoraria, research funding to institution
RGCON - Rajiv Gandi Conference			✓		International Professional Society conferences (Travel funding)
JLCS - Japanese Lung Cancer Society			✓		International Professional Society conferences (Travel funding)
KSMO - Korean Society of Medical Oncology			✓		International Professional Society conferences (Travel funding)
Stanford University			✓		Professor of Medicine
TMIG			✓		Scientific Advisory Committee (travel funding)
ACEA Biosciences				✓	Research funding to institution
Arrys Therapeutics				✓	Research funding to institution



AztraZeneca/MedImmune				✓	Research funding to institution	
BMS				✓	Research funding to institution	
Celgene				✓	Research funding to institution	
Clovis Oncology				✓	Research funding to institution	
Exelixis				✓	Research funding to institution	
Lilly				✓	Research funding to institution	
Pfizer				✓	Research funding to institution	
Pharmacyclics				✓	Research funding to institution	
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V						
Section 5. Relationsh	nips not covere	ed above				
Are there other relationships of potentially influencing, what y			•	influence	ed, or that give the appearance of	
Yes, the following relation:	ships/conditions	/circumstand	ces are present (ex	plain bel	ow):	
✓ No other relationships/cor	nditions/circums	tances that p	resent a potential	conflict o	of interest	
At the time of manuscript according to the common of the c					ssary, update their disclosure statemen	



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Wakelee reports grants from Gilead, personal fees and non-financial support from AztraZeneca, personal fees and other from Xcovery, personal fees from Janssen, personal fees from Daiichi Sankyo, INC, personal fees from Helsinn, personal fees from Mirati, non-financial support from Takeda, non-financial support from CellWorks, non-financial support and other from Genentech/Roche, non-financial support and other from Merck, non-financial support from Clinical Care Options Oncology, LLC, non-financial support from Fishawack Facilitate LTD, non-financial support from Medscape, non-financial support from Onclive/Intellisphere LLC, non-financial support from Phillips Gilmore Oncology (2018), non-financial support from Physicians Education Resource LLC/MJH (Targeted Oncology), non-financial support from Potomac Center for Medical Education (Rockpointe), non-financial support from Prime Oncology LLC (2018), non-financial support from Primo (2018), non-financial support from Research to Practice, personal fees from UpToDate, non-financial support from WebMD Health, non-financial support from Novartis, non-financial support from RGCON - Rajiv Gandi Conference, non-financial support from JLCS - Japanese Lung Cancer Society, non-financial support from KSMO - Korean Society of Medical Oncology, non-financial support from Stanford University, non-financial support from ITMIG, other from ACEA Biosciences, other from Arrys Therapeutics, other from AztraZeneca/MedImmune, other from BMS, other from Celgene, other from Clovis Oncology, other from Exelixis, other from Lilly, other from Pfizer, other from Pharmacyclics, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.